



FOR IMMEDIATE RELEASE

to-BBB and Sihuan Enter into Collaboration Agreement

Partnership Aims to Expand the R&D Pipeline and Gain Access to the Chinese Market

Leiden, the Netherlands, 11 December 2013 - [to-BBB](#), the brain drug development company, is entering into a collaboration agreement with Sun Moral International (HK) Limited, a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Limited ([Sihuan](#)). The agreement aims at the collaborative research and development of innovative drugs for Central Nervous System (CNS) diseases.

to-BBB and Sihuan will conduct feasibility studies by applying to-BBB's G-Technology®, a patented brain drug delivery technology for sustained release and [enhanced brain delivery](#), to certain drug compounds owned by Sihuan. Based on the successful completion of the feasibility studies, both parties desire to enter into a commercial license agreement for collaborative development of one or more drug compounds using to-BBB's G-Technology. Sihuan shall pursue the approval of the developed products in China.

“Sihuan entered into the collaboration agreement with the aim to tap the high unmet medical need of drug products with sustained delivery to the CNS,” says Dr. Che FengSheng, CEO and Chairman of Sihuan. “The collaboration will combine the research efforts of to-BBB's brain-targeting technology and Sihuan's R&D resources in oncology and CNS. The R&D program will be overseen by a joint steering committee with representatives from to-BBB and Sihuan. The two parties will share the achievements of the R&D project.”

“We are pleased by Sihuan's recognition that the G-Technology offers the safest possibility to enhance the delivery of drugs across the blood-brain barrier, aiming at therapeutic approaches for treating devastating CNS diseases,” says Dr. Pieter Gaillard, CSO of to-BBB. “This unique approach has obtained multiple pre-clinical and clinical validations, including the development of to-BBB's lead product 2B3-101 for brain cancer that is currently in a Phase IIa trial.”

About Sihuan

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a leading pharmaceutical company and the largest cardio-cerebral vascular drug franchise in China's prescription drug market by market share. The success of the Company can be attributed to its differentiated and proven sales and marketing model, diversified portfolio of market leading drugs, extensive nationwide distribution network, and strong research and development capabilities. Sihuan Pharmaceutical major products such as Kelinao, Anjieli, Chuanqing, Qu'Ao, GM1 and Oudimei are widely used in the treatment of various cardio-cerebral vascular diseases.

About to-BBB

to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines

existing drugs with to-BBB's proprietary G-Technology for enhanced drug delivery across the blood-brain barrier. This platform technology combines the widely used drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. to-BBB's lead product 2B3-101 is investigated in a Phase IIa trial for the treatment of primary brain tumors as well as brain metastases. to-BBB's second product 2B3-201 for MS relapses and other neuroinflammatory diseases will enter into a Phase I clinical study by the end of 2013.

to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

For more information,

Corporate Contacts:

Willem van Weperen, MSc, MBA
Chief Executive Officer

Phone: +31 71 33 222 51

E-mail: WillemVanWeperen@toBBB.com

Sijme Zeilemaker, MSc

Business Development Manager

Phone: +31 71 33 222 56

E-mail: SijmeZeilemaker@toBBB.com

to-BBB technologies BV

J.H. Oortweg 19
2333 CH Leiden
The Netherlands
www.toBBB.com

to-BBB technologies BV

J.H. Oortweg 19
2333 CH Leiden
The Netherlands
www.toBBB.com